01356nas a2200433   4500000000100000000000100001000000100002008004100003653004800044653001000092653006100102653004500163653004500208653001900253653001100272653001100283653006300294653002400357653005700381653002300438653003700461653004500498653001800543653002900561653001500590653001700605653001500622653001100637100001500648700001600663700001600679700001400695700001500709245015000724250001500874300001200889490000700901020001400908       2022                            d10aAdrenergic beta-Antagonists/therapeutic use10aAdult10aAngiotensin-Converting Enzyme Inhibitors/therapeutic use10a*Antihypertensive Agents/therapeutic use10aCalcium Channel Blockers/therapeutic use10aCohort Studies10aFemale10aHumans10a*Hypertension/chemically induced/drug therapy/epidemiology10aPrimary health care10aSodium Chloride Symporter Inhibitors/therapeutic use10aThiazide diuretics10aangiotensin II receptor blockers10aangiotensin-converting enzyme inhibitors10abeta-blockers10acalcium channel blockers10afirst-line10ahypertension10atrajectory10atrends1 aJ. Rouette1 aE. McDonald1 aT. Schuster1 aJ. Brophy1 aL. Azoulay00aTreatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study  a2022/06/11  ae0575100 v12  a2044-6055